NYSE · ANVS
Healthcare · Biotechnology
$1.20
Down-$0.02 (-1.67%)
Updated Oct 6, 2026, 11:28 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ANVS
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
ANVS closed at $1.20 after 20 trading sessions, down 7.69% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $1.16 | $1.20 | $1.135 | $1.20 | 657.64K |
| Oct 2, 2026 | $1.19 | $1.1964 | $1.135 | $1.18 | 648.54K |
| Oct 1, 2026 | $1.27 | $1.28 | $1.16 | $1.17 | 1.2M |
| Sep 30, 2026 | $1.30 | $1.335 | $1.27 | $1.27 | 572.99K |
| Sep 29, 2026 | $1.39 | $1.41 | $1.30 | $1.30 | 812.05K |
| Sep 28, 2026 | $1.32 | $1.43 | $1.30 | $1.38 | 1.2M |
| Sep 25, 2026 | $1.35 | $1.36 | $1.305 | $1.31 | 573.62K |
| Sep 24, 2026 | $1.27 | $1.34 | $1.23 | $1.33 | 855.17K |
| Sep 23, 2026 | $1.30 | $1.33 | $1.235 | $1.27 | 1.15M |
| Sep 22, 2026 | $1.19 | $1.30 | $1.185 | $1.26 | 1.21M |
| Sep 21, 2026 | $1.16 | $1.22 | $1.16 | $1.19 | 885.9K |
| Sep 18, 2026 | $1.12 | $1.16 | $1.09 | $1.14 | 681.98K |
| Sep 17, 2026 | $1.10 | $1.17 | $1.08 | $1.10 | 1.52M |
| Sep 16, 2026 | $1.12 | $1.13 | $1.04 | $1.04 | 1.43M |
| Sep 15, 2026 | $1.14 | $1.14 | $1.10 | $1.12 | 824.33K |
| Sep 14, 2026 | $1.10 | $1.17 | $1.095 | $1.14 | 1.2M |
| Sep 11, 2026 | $1.20 | $1.2307 | $1.10 | $1.12 | 1.89M |
| Sep 10, 2026 | $1.21 | $1.26 | $1.17 | $1.19 | 1.34M |
| Sep 9, 2026 | $1.31 | $1.32 | $1.22 | $1.22 | 1.75M |
| Sep 8, 2026 | $1.39 | $1.3981 | $1.30 | $1.30 | 1.96M |
The latest Smart Investors Daily articles mentioning ANVS.
Company
Market Activity
Research & News
ANVS research
Company profile and research snapshot.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 28, 2026 | Roth Capital | Buy | — |
| Aug 18, 2026 | Canaccord Genuity | Buy | — |
| Jul 8, 2026 | Roth Capital | Buy | — |
| Apr 14, 2026 | Canaccord Genuity | Buy | — |
| Sep 30, 2025 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Finnhub · Apr 13, 2026
MALVERN, Pa. - Annovis Bio, Inc. , a Phase 3 clinical - stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease...
Benzinga · Apr 10, 2026
Financing secures path to first NDA submission for buntanetap6-Month symptomatic data readout anticipated Q1 2027Alzheimer's disease Phase 3 trial 75% enrolledParkinson's disease open-label study 28% enrolledMALVERN,
Fintel · Apr 9, 2026
Benzinga · Apr 9, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ANVS.
